{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:07:53Z","timestamp":1760346473530,"version":"3.41.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T00:00:00Z","timestamp":1443052800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12859-015-0730-x","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T11:41:32Z","timestamp":1443094892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib"],"prefix":"10.1186","volume":"16","author":[{"given":"Bjoern-Oliver","family":"Gohlke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Overkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Gillissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,24]]},"reference":[{"issue":"9-10","key":"730_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","volume":"18","author":"JL Medina-Franco","year":"2013","unstructured":"Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today. 2013;18(9-10):495\u2013501.","journal-title":"Drug Discov Today"},{"issue":"8","key":"730_CR2","first-page":"669","volume":"11","author":"E Gregori-Puigjane","year":"2008","unstructured":"Gregori-Puigjane E, Mestres J. A ligand-based approach to mining the chemogenomic space of drugs. Com Chem High t Scr. 2008;11(8):669\u201376.","journal-title":"Com Chem High t Scr"},{"issue":"8","key":"730_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bioinformatics\/16.8.747","volume":"16","author":"A Lagunin","year":"2000","unstructured":"Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: prediction of activity spectra for biologically active substances. Bioinformatics. 2000;16(8):747\u20138.","journal-title":"Bioinformatics"},{"issue":"Database issue","key":"730_CR4","doi-asserted-by":"publisher","first-page":"D1060","DOI":"10.1093\/nar\/gkq1037","volume":"39","author":"J Eichborn von","year":"2011","unstructured":"von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 2011;39(Database issue):D1060\u20131066.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"730_CR5","doi-asserted-by":"publisher","first-page":"e22187","DOI":"10.1371\/journal.pone.0022187","volume":"6","author":"L Brouwers","year":"2011","unstructured":"Brouwers L, Iskar M, Zeller G, van Noort V, Bork P. Network neighbors of drug targets contribute to drug side-effect similarity. PLoS One. 2011;6(7):e22187.","journal-title":"PLoS One"},{"issue":"12","key":"730_CR6","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1021\/ci2005548","volume":"52","author":"Y Yamanishi","year":"2012","unstructured":"Yamanishi Y, Pauwels E, Kotera M. Drug side-effect prediction based on the integration of chemical and biological spaces. J Chem Inf Model. 2012;52(12):3284\u201392.","journal-title":"J Chem Inf Model"},{"issue":"6","key":"730_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/ci9800211","volume":"38","author":"P Willett","year":"1998","unstructured":"Willett P, Barnard JM, Downs GM. Chemical similarity searching. J Chem Inf Comp Sci. 1998;38(6):983\u201396.","journal-title":"J Chem Inf Comp Sci"},{"key":"730_CR8","doi-asserted-by":"crossref","unstructured":"Godden JW, Xue L, Stahura FL, Bajorath J: Searching for molecules with similar biological activity: analysis by fingerprint profiling. Pac Symp Biocomput 2000;8:566-575","DOI":"10.1142\/9789814447331_0054"},{"issue":"3","key":"730_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1021\/ci034001x","volume":"43","author":"JD Holliday","year":"2003","unstructured":"Holliday JD, Salim N, Whittle M, Willett P. Analysis and display of the size dependence of chemical similarity coefficients. J Chem Inf Comp Sci. 2003;43(3):819\u201328.","journal-title":"J Chem Inf Comp Sci"},{"issue":"5","key":"730_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1021\/cb300003z","volume":"7","author":"C Rademacher","year":"2012","unstructured":"Rademacher C, Paulson JC. Glycan fingerprints: calculating diversity in glycan libraries. ACS Chem Biol. 2012;7(5):829\u201334.","journal-title":"ACS Chem Biol"},{"issue":"Database issue","key":"730_CR11","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"40","author":"A Gaulton","year":"2012","unstructured":"Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40(Database issue):D1100\u20131107.","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"730_CR12","doi-asserted-by":"publisher","first-page":"W623","DOI":"10.1093\/nar\/gkp456","volume":"37","author":"Y Wang","year":"2009","unstructured":"Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009;37(Web Server issue):W623\u2013633.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"730_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin JJ, Shoichet BK. ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45(1):177\u201382.","journal-title":"J Chem Inf Model"},{"issue":"Database issue","key":"730_CR14","first-page":"D919","volume":"36","author":"S Gunther","year":"2008","unstructured":"Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res. 2008;36(Database issue):D919\u2013922.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"730_CR15","doi-asserted-by":"publisher","first-page":"D1113","DOI":"10.1093\/nar\/gkr912","volume":"40","author":"N Hecker","year":"2012","unstructured":"Hecker N, Ahmed J, von Eichborn J, Dunkel M, Macha K, Eckert A, et al. SuperTarget goes quantitative: update on drug-target interactions. Nucleic Acids Res. 2012;40(Database issue):D1113\u20131117.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"730_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1634\/theoncologist.12-4-443","volume":"12","author":"M Los","year":"2007","unstructured":"Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007;12(4):443\u201350.","journal-title":"Oncologist"},{"issue":"1","key":"730_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","volume":"117","author":"JJ Raizer","year":"2014","unstructured":"Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, et al. A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117(1):93\u2013101.","journal-title":"J Neurooncol"},{"issue":"4","key":"730_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clgc.2013.11.020","volume":"12","author":"RL Bitting","year":"2014","unstructured":"Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, et al. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014;12(4):241\u201350.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"730_CR19","first-page":"2178","volume":"60","author":"JM Wood","year":"2000","unstructured":"Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178\u201389.","journal-title":"Cancer Res"},{"issue":"1","key":"730_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/qsar.19860050105","volume":"5","author":"P Willett","year":"1986","unstructured":"Willett P, Winterman V. A comparison of some measures for the determination of intermolecular structural similarity measures of intermolecular structural similarity. Quant Struct-Act Rel. 1986;5(1):18\u201325.","journal-title":"Quant Struct-Act Rel"},{"issue":"5","key":"730_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M. Extended-connectivity fingerprints. J Chem Inf Model. 2010;50(5):742\u201354.","journal-title":"J Chem Inf Model"},{"issue":"2","key":"730_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1021\/c160017a018","volume":"5","author":"HL Morgan","year":"1965","unstructured":"Morgan HL. Generation of a unique machine description for chemical structures-a technique developed at chemical abstracts service. J Chem Doc. 1965;5(2):107\u201313.","journal-title":"J Chem Doc"},{"issue":"Sep1","key":"730_CR23","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1107\/S0567739476001873","volume":"32","author":"W Kabsch","year":"1976","unstructured":"Kabsch W. Solution for best rotation to relate 2 sets of vectors. Acta Crystallogr A. 1976;32(Sep1):922\u20133.","journal-title":"Acta Crystallogr A"},{"issue":"10","key":"730_CR24","first-page":"4175","volume":"61","author":"E Perkins","year":"2001","unstructured":"Perkins E, Sun D, Nguyen A, Tulac S, Francesco M, Tavana H, et al. Novel inhibitors of poly(ADP-ribose) polymerase\/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res. 2001;61(10):4175\u201383.","journal-title":"Cancer Res"},{"issue":"2","key":"730_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T","volume":"43","author":"DJ Diller","year":"2001","unstructured":"Diller DJ, Merz Jr KM. High throughput docking for library design and library prioritization. Proteins. 2001;43(2):113\u201324.","journal-title":"Proteins"},{"issue":"18","key":"730_CR26","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-10-0523","volume":"16","author":"CE Redon","year":"2010","unstructured":"Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res. 2010;16(18):4532\u201342.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"730_CR27","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1021\/bi00555a022","volume":"19","author":"MH West","year":"1980","unstructured":"West MH, Bonner WM. Histone 2A, a heteromorphous family of eight protein species. Biochemistry. 1980;19(14):3238\u201345.","journal-title":"Biochemistry"},{"issue":"10","key":"730_CR28","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858\u201368.","journal-title":"J Biol Chem"},{"key":"730_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1385\/1-59259-973-7:073","volume":"314","author":"X Huang","year":"2006","unstructured":"Huang X, Darzynkiewicz Z. Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage. Methods Mol Biol. 2006;314:73\u201380.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"730_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/ci0001482","volume":"41","author":"J Bajorath","year":"2001","unstructured":"Bajorath J. Selected concepts and investigations in compound classification, molecular descriptor analysis, and virtual screening. J Chem Inf Comp Sci. 2001;41(2):233\u201345.","journal-title":"J Chem Inf Comp Sci"},{"issue":"5","key":"730_CR31","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1021\/ci049920h","volume":"44","author":"M Thimm","year":"2004","unstructured":"Thimm M, Goede A, Hougardy S, Preissner R. Comparison of 2D similarity and 3D superposition. Application to searching a conformational drug database. J Chem Inf Comp Sci. 2004;44(5):1816\u201322.","journal-title":"J Chem Inf Comp Sci"},{"issue":"23","key":"730_CR32","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1093\/bioinformatics\/btt540","volume":"29","author":"D Gfeller","year":"2013","unstructured":"Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive molecules. Bioinformatics. 2013;29(23):3073\u20139.","journal-title":"Bioinformatics"},{"issue":"6","key":"730_CR33","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.3390\/molecules19067008","volume":"19","author":"K Dobi","year":"2014","unstructured":"Dobi K, Hajdu I, Flachner B, Fabo G, Szaszko M, Bognar M, et al. Combination of 2D\/3D ligand-based similarity search in rapid virtual screening from multimillion compound repositories. Selection and biological evaluation of potential PDE4 and PDE5 inhibitors. Molecules. 2014;19(6):7008\u201339.","journal-title":"Molecules"},{"issue":"23","key":"730_CR34","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1021\/jm010116l","volume":"44","author":"G Costantino","year":"2001","unstructured":"Costantino G, Macchiarulo A, Camaioni E, Pellicciari R. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. J Med Chem. 2001;44(23):3786\u201394.","journal-title":"J Med Chem"},{"issue":"3","key":"730_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/1087057103008003013","volume":"8","author":"KJ Dillon","year":"2003","unstructured":"Dillon KJ, Smith GC, Martin NM. A FlashPlate assay for the identification of PARP-1 inhibitors. J Biomol Screen. 2003;8(3):347\u201352.","journal-title":"J Biomol Screen"},{"issue":"10","key":"730_CR36","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.24213","volume":"115","author":"DA Reardon","year":"2009","unstructured":"Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009;115(10):2188\u201398.","journal-title":"Cancer"},{"issue":"18","key":"730_CR37","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2005.09.034","volume":"23","author":"AL Thomas","year":"2005","unstructured":"Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol. 2005;23(18):4162\u201371.","journal-title":"J Clin Oncol"},{"issue":"21","key":"730_CR38","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1200\/JCO.2003.08.092","volume":"21","author":"B Morgan","year":"2003","unstructured":"Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787\/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21(21):3955\u201364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"730_CR39","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1124\/dmd.106.009944","volume":"34","author":"LM Jost","year":"2006","unstructured":"Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, et al. Metabolism and disposition of vatalanib (PTK787\/ZK-222584) in cancer patients. Drug Metab Dispos. 2006;34(11):1817\u201328.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"730_CR40","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-08-4711","volume":"69","author":"S Banerjee","year":"2009","unstructured":"Banerjee S, Zvelebil M, Furet P, Mueller-Vieira U, Evans DB, Dowsett M, et al. The vascular endothelial growth factor receptor inhibitor PTK787\/ZK222584 inhibits aromatase. Cancer Res. 2009;69(11):4716\u201323.","journal-title":"Cancer Res"},{"issue":"16","key":"730_CR41","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1158\/1078-0432.CCR-10-0456","volume":"16","author":"S Banerjee","year":"2010","unstructured":"Banerjee S, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, et al. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787\/ZK222584 in vivo. Clin Cancer Res. 2010;16(16):4178\u201387.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"730_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.sbi.2006.01.013","volume":"16","author":"AL Hopkins","year":"2006","unstructured":"Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol. 2006;16(1):127\u201336.","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"730_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2174\/092986708783503212","volume":"15","author":"A Petrelli","year":"2008","unstructured":"Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008;15(5):422\u201332.","journal-title":"Curr Med Chem"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-015-0730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-015-0730-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-015-0730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T19:58:30Z","timestamp":1748635110000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-015-0730-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,24]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/s12859-015-0730-x","relation":{},"ISSN":["1471-2105"],"issn-type":[{"type":"electronic","value":"1471-2105"}],"subject":[],"published":{"date-parts":[[2015,9,24]]},"article-number":"308"}}